Lirimilast( BAY 19-8004 | BAY 198004 )

Catalog No. M14085 CAS No. 329306-27-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Lirimilast
Note

Research use only, not for human use.
Brief Description

Lirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.
Description

Lirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.COPD Phase 2 Discontinued.
In Vitro

In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL.
In Vivo

Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation.
Synonyms

BAY 19-8004 | BAY 198004
Pathway

Angiogenesis
Target

PDE
Recptor

PDE
Research Area

Inflammation/Immunology
Indication

COPD

CAS Number

329306-27-6
Formula Weight

443.251
Molecular Formula

C17H12Cl2N2O6S
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (225.60 mM)
SMILES

CS(=O)(OC1=CC=C2C(NC(N)=O)=C(C(C3=CC=C(Cl)C=C3Cl)=O)OC2=C1)=O
Chemical Name

[3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate

1. Grootendorst DC, et al. Pulm Pharmacol Ther. 2003;16(6):341-7.

Calculator

molnova catalog